Sitravatinib

Generic Name: Sitravatinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₂₉F_₂N_₅O_₄S

CAS Number: 1123837-84-2

Unique Ingredient Identifier: CWG62Q1VTB

Background: Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

Phase 2

Withdrawn

Conditions: Metastatic Cervical Cancer

Interventions: Drug: Tislelizumab
Drug: Sitravatinib

First Posted Date: 2022-11-14

Last Posted Date: 2023-06-29

Lead Sponsor: Australia New Zealand Gynaecological Oncology Group

Registration Number: NCT05614453

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Phase 3

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Tislelizumab
Drug: sitravatinib-matching placebo
Drug: Sitravatinib
Drug: tislelizumab-matching placebo

First Posted Date: 2022-10-03

Last Posted Date: 2023-06-07

Lead Sponsor: BeiGene

Registration Number: NCT05564338

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Sitravatinib
Drug: Docetaxel
Drug: Tislelizumab
Drug: Irinotecan

First Posted Date: 2022-07-18

Last Posted Date: 2024-03-04

Lead Sponsor: BeiGene

Target Recruit Count: 96

Registration Number: NCT05461794

Locations: 🇨🇳
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan, China
🇨🇳
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China

and more 24 locations

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Phase 2

Withdrawn

Conditions: Recurrent Endometrial Cancer
Solid Tumors

Interventions: Drug: pembrolizumab
Drug: Sitravatinib

First Posted Date: 2022-06-15

Last Posted Date: 2023-02-27

Lead Sponsor: Haider Mahdi

Registration Number: NCT05419817

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Phase 2

Active, not recruiting

Conditions: Lung Cancer, Small Cell

Interventions: Drug: Tislelizumab
Drug: Sitravatinib

First Posted Date: 2022-02-08

Last Posted Date: 2023-09-26

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 21

Registration Number: NCT05228496

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Sitravatinib

First Posted Date: 2022-01-04

Last Posted Date: 2024-01-29

Lead Sponsor: Fudan University

Target Recruit Count: 5

Registration Number: NCT05176925

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Phase 2

Conditions: Melanoma

Interventions: Drug: sitravatinib
Drug: tislelizumab

First Posted Date: 2021-11-03

Last Posted Date: 2021-11-04

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 37

Registration Number: NCT05104801

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Study to Explore the Effect of Acid-reducing Agents

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: Sitravatinib
Drug: Pantoprazole
Drug: Famotidine

First Posted Date: 2021-06-22

Last Posted Date: 2022-08-26

Lead Sponsor: Mirati Therapeutics Inc.

Target Recruit Count: 15

Registration Number: NCT04935112

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Phase 2

Terminated

Conditions: Lung Neoplasms
Metastatic Lung Non-Small Cell Carcinoma
Sitravatinib
Carcinoma, Non-Small-Cell Lung
PD-L1 Gene Mutation
Advanced Treatment-Naïve PD-L1
Lung Diseases
Stage IV Lung Non-Small Cell Cancer AJCC v7
Pembrolizumab

Interventions: Drug: Sitravatinib
Drug: Pembrolizumab

First Posted Date: 2021-06-14

Last Posted Date: 2024-01-30

Lead Sponsor: Sarah Goldberg

Target Recruit Count: 9

Registration Number: NCT04925986

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Tislelizumab
Drug: Docetaxel
Drug: Sitravatinib

First Posted Date: 2021-06-10

Last Posted Date: 2024-02-28

Lead Sponsor: BeiGene

Target Recruit Count: 377

Registration Number: NCT04921358

Locations: 🇨🇳
Xinqiao Hospital Affiliated to the Army Medical University, Chongqing, Chongqing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇦🇺
The Northern Hospital, Epping, Victoria, Australia

and more 60 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy